On September 22, BioStock’s Investing in Life Science 2026 event took place in Stockholm. This exclusive investor event brings together leading life science companies from across the region with investors seeking new opportunities and strategic partnerships at various stages of development. The event provides an excellent opportunity to exchange ideas, build meaningful relationships, and explore potential collaborations within the Nordic life science community.
Abarceo participated in the event. “It was an exciting event where I presented Abarceo’s latest steps towards creating a first oral disease-modifying treatment for Type1 Diabetes and our platform to treat mitochondrial dysfunction”, says Abarceo’s CEO Adam Bruce, who attended and spoke at the event on September 22.
Recent Comments